Abstract:

Avian influenza is one of the deadly infectious diseases of poultry, which influences the development of agricultural economy of China greatly. Highly pathogenic avian influenza (HPAI) virus like H5N1 can even break the species barrier and infect human, which may pose great threat to public health. Currently, inactivated vaccines are the main vaccine in preventing avian influenza, which may accelerate virus transmission if we can’t get the virus completely inactivated. Therefore, we need safer and more effective vaccines. In this study, we constructed a recombinant baculovirus BV-G-H5N1-HA, expressing HA protein in mammalian cell and exhibiting HA protein on the surface of the viral envelope simultaneously. Animal experiment was conducted by vaccinating mice intramuscularly with BV-G-H5N1-HA, pc-H5N1-HA, AcMNPV-WT (wild-type AcMNPV) and PBS, respectively, then the mice were challenged intranasally (i.n.) with A/Chicken/Guangzhou/M/2008(H5N1). Results showed that BV-G-H5N1l-HA can induce higher concentrations of neutralizing antibody and HI antibody in the immune group, and provide a considerable protection rate of 91.7%. All these data indicate that BV-G-H5N1-HA may be a novel vaccine candidate which helps to prevent and control of HPAI in the future. Moreover, the application of novel baculovirus vector will provide important insights into the field of animal vaccine development.